OTCBB ALERTS

[Mandroid]

APHT - NEWS -BioWa, Inc. and Aphton Corporation (Pink Sheets:APHT)
today announced that BioWa has granted a non-exclusive license to
Apthon's wholly-owned subsidiary, Igeneon, to use BioWa's
POTELLIGENT(TM) technology for the development of IGN312, a humanized
monoclonal Lewis Y-specific antibody. Aphton, through Igeneon,
develops IGN312 as a next-generation antibody based on IGN311, which
is currently in a Phase I/II clinical trial in patients with Lewis
Y-positive cancers.
Aphton plans to use BioWa's POTELLIGENT technology for the
development of a next-generation Lewis Y-specific antibody with
enhanced antibody-dependent cellular cytotoxicity (ADCC). Lewis Y is a
tumor-related antigen expressed in up to 90% of all epithelial
cancers, which include breast, colon, gastric and pancreatic cancers.
BioWa's POTELLIGENT technology has the potential to increase the ADCC
activity of an antibody, resulting in greater capacity to destroy
tumor cells.
"We are very pleased to be working with an innovative cancer
immunotherapy company like Igeneon, who has successfully progressed
its antibody program to the clinical stage," said Nobuo Hanai, Ph.D.,
President and CEO of BioWa, Inc. "This licensing agreement enforces
BioWa's strategy to bring about more effective and safe treatments for
cancer."
"We look forward to the rapid application of the POTELLIGENT
technology, which has the potential to effectively increase the
potency of IGN312 as an anti-cancer treatment," said Patrick Mooney,
MD, Chairman and CEO of Aphton Corporation. "Entering into this
partnership with BioWa is an important step in our efforts to continue
to develop promising product candidates to fuel our clinical pipeline
in the future."
This agreement was mediated by FHR Consult
(http://www.fhrconsult.com) on behalf of BioWa.

About IGN311 and IGN312

IGN311 is a humanized monoclonal antibody against the Lewis Y
carbohydrate antigen, a blood-group-related oligosaccharide. Lewis Y
is over-expressed in up to 90% of all epithelial cancers and its
expression on adult normal tissues is very restricted; hence IGN311
has the potential to target a broad range of carcinomas. IGN311 is
designed to exert clinical effects by destruction of tumor cells by
activation of effector functions and by selective growth inhibition
via functional receptors. IGN312 is a next-generation antibody based
on IGN311.

About Aphton Corporation